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Abstract
This feasibility study was designed to assess the ability to measure 
mitochondrial DNA (mtDNA) in cerebrospinal fluid (CSF) cells that 
contributed to minimal disease/persistent or residual disease (MD/
PRD)  from  children  with  acute  lymphoblastic  leukemia  (ALL). 
Increase in mtDNA copies in cancer cells has been suggested to 
play a role in MD/PRD. CSF as well as blood specimens from 6 
children were assayed for MD/PRD and mtDNA copy numbers 
by  quantitative  real-time  polymerase  chain  reaction.  Of  7  MD/
PRD-positive specimens, 6 had increased mtDNA copy numbers; 
while 11 MD/PRD-negative specimens had no increase in mtDNA 
copy numbers, p < 0.003. This is the first proof-of-concept study 
to  measure  mtDNA  copy  numbers  in  MD/PRD-positive  CSF 
specimens  from  children  with  ALL.  Increase  of  mtDNA  copy 
numbers in MD/PRD childhood ALL cells and its significance as a 
mechanism for recurrence requires further investigation.  
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Introduction
The presence of minimal disease/persistent or residual dis-
ease (MD/PRD) is associated with poor prognosis in child-
hood acute lymphoblastic leukemia (ALL) [1-6]. In iden-
tifying presence of MD/PRD as a risk factor, Schultz et al 
developed an algorithm using MD to help guide treatment 
for B-precursor ALL [7]. The significance of MD/PRD pres-
ence during ALL therapy lies in the possibility that residual 
leukemic cells could represent a survival phenotype leading 
to recurrence of disease. Recent studies by Kusao et al sug-
gest that malignant cells might be able to overcome chemo-
toxicity by increasing the number of mitochondrial DNA 
(mtDNA) which could translate to increase energy produc-
tion leading to malignant cell survival [8, 9]. From clinical 
specimens,  those  which  were  positive  for  MD/PRD  had 
increased mtDNA copies per cell compared to specimens 
which were negative for MD/PRD [8]. Kusao et al hypoth-
esized that surviving malignant cells exposed to chemother-
apy would compensate by increasing mtDNA copies which 
was demonstrated through in vitro experiments [8].   
Assessing  MD/PRD  in  the  cerebrospinal  fluid  (CSF) 
provides additional challenges due to the relatively small 
number  of  cells.  However,  when  central  nervous  system 
(CNS) relapse is diagnosed from analyzing CSF cells, the 
percentages of CSF lymphoblasts is relatively high compared 
to  analyses  of  peripheral  blood  lymphoblast  percentages. 
Thus on a per-cell basis, recognizing the opportunity to study 
mtDNA copies in CSF lymphoblasts provided the mechanism 
for the proof-of-concept study to determine if mtDNA copy 
numbers  could  be  measured  in  CSF  lymphoblasts  from 
clinical  specimens  positive  for  MD/PRD.  We  posit  that 
CSF  and  peripheral  blood  specimens,  which  are  positive 
for MD/PRD, would have increased mtDNA copy numbers 
compared to MD/PRD-negative specimens.
Patients and Methods
Patients and specimens  
CSF cells and peripheral blood mononuclear cells (PBMC) 
were  obtained  from  a  tissue  repository  which  had  previ-
ously processed and stored CSF and blood from pediatric 
ALL cases without patient identifiers as per guidelines by 
the University of Hawaii Institutional Review Board.  Cases 
were selected from the repository from which diagnostic and 
follow-up specimens were available for CSF; and two con-
secutive follow-up specimens available for PBMC; all from 
children diagnosed with pre-B-cell ALL. Age, gender, and 
limited clinical data were available for each case.
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Minimal residual disease and mitochondrial DNA assess-
ments 
The PBMC and CSF samples were previously assessed for 
MD/PRD [10, 11]. Briefly, the strategy for MD/PRD identi-
fication used patient-specific primers (PSP) from consensus 
primers of the third complementary determining region of 
the immunoglobulin heavy chain region and T-cell receptor-
delta/gamma regions [10-12]. The identified PSP from the 
diagnostic specimen was then used as a marker to assess 
MD/PRD  in  follow-up  specimens.  The  sensitivity  of  the 
MD/PRD assay was 1 in 100,000 cells.
          All MD/PRD-positive and MD/PRD-negative speci-
mens from the repository were repurified by ethanol precipi-
tation, reconstituted in Tris-HCl-EDTA buffer, and found to 
be adequate in quantity and quality by UV spectrophotom-
etry. Using techniques previously established in the labora-
tory, a multiplex real-time PCR assay was performed on each 
DNA specimen to amplify a Fas ligand nuclear region and 
a region of the mtDNA [8]. Briefly, dilutions of a control 
plasmid ranging from 102 copies to 106 copies containing a 
specific portion of mtDNA and the genomic sequence were 
prepared to establish the standard curves. The mitochondrial 
primers (forward: CAC AGA AGC TGC CAT CAA GTA; re-
verse: CCG GAG AGT ATA TTG TTG AAG AG) amplified 
the mtDNA region encoding the NADH dehydrogenase sub-
unit 2, while the genomic primers (forward: GGC TCT GTG 
AGG GAT ATA AAG ACA; reverse: CAA ACC ACC CGA 
GCA ACTAAT CT) amplified the encoding region for Fas 
ligand. DNA from the specimens and appropriate positive/
negative controls were set up in either duplicate or triplicate 
with each reaction containing iQ SYBR Green Supermix, 10 
pmol forward primer and 10 pmol reverse primer with cy-
cling parameters: 95°C for 1 min; 40 cycles of 95°C for 30 
sec; 58.9°C for 40 sec; 72°C for 4 min; and 50°C for 30 sec. 
At the conclusion of the PCR, melt curve data were collected 
from a starting temperature of 65°C, with 0.5°C incremental 
increases every 5 sec for duration of 70 cycles. Copy num-
bers of mtDNA were obtained as previously reported with 
the average mtDNA copy number in PBMC or non-malig-
nant cells ranging from 60-100 copies per cell [13].  
Statistical analysis
The Mann-Whitney test was used to determine the associa-
tions between the mtDNA copy numbers/cell in the MD/
PRD-negative and MD/PRD-positive specimens. Statistical 
analyses were performed using SPSS, Version 16 (Chicago, 
IL).
Results
Fourteen CSF samples from four children diagnosed with 
B-cell ALL and four additional PBMC specimens from two 
children with the same diagnoses were available from the tis-
sue repository which comprised of diagnostic and follow-up 
specimens. Gender, age, and clinical course of the children 
are summarized in Table 1. For the cases from which CSF 
were available, CSF was obtained at the time of diagnosis, 
one month from beginning of induction therapy (Visit 1), 4 - 
6 months from the beginning of induction therapy (Visit 2), 
and, when possible, 10 - 12 months from the beginning of 
induction therapy (Visit 3) (Fig. 1). In comparison and con-
trast, the cases for which PBMC specimens were available, 
Visits 1 and 2 corresponded to one and two months post-
induction therapy, respectively. Of the 14 CSF specimens, 
five were positive for MD/PRD (Fig. 1A). Of the 5/14 MD/
PRD-positive CSF specimens, four had increased mtDNA 
copy numbers compared to normal mtDNA copy numbers 
in PBMC from normal controls and compared to MD/PRD-
negative CSF specimens, p < 0.003.
Table 1. Subject Demographics and Clinical Characteristics with ALL
Age 
(years)
Gender Clinical Course and Characteristics
Patient 1
    
    5
     
      M No CNS disease; remission at EOT
Patient 2     7       M No CNS disease; remission at EOT
Patient 3     6       F CNS disease at diagnosis; CNS relapse in Year 1; remission at EOT
Patient 4     7       M CNS disease at diagnosis; CNS relapse in Year 1; remission at EOT
Patient 5     8       M No CNS disease; bone marrow relapse at 6 months; remission at EOT
Patient 6     6       M No CNS disease; bone marrow relapse at 8 months; remission at EOT
M: male; F: female; CNS: central nervous system; EOT: end of therapy
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       Analysis of the clinical course and CSF specimens from 
Patient 1 showed that the child remained in clinical remis-
sion with no clinical CNS relapse; and this was reflected in 
the MD/PRD-negative status of the CSF diagnostic and fol-
low-up specimens. The diagnostic and follow-up mtDNA as-
sessment of the MD/PRD-negative CSF specimens showed 
that the mtDNA copy number remained relatively stable and 
within the normal range measured in non-malignant cells 
(60 - 100 copies/cell) (Fig. 1A). Similarly, Patient 2 also re-
mained in clinical remission with no CNS disease at diag-
nosis or in follow-up. However, a CSF specimen from Visit 
2 (4 - 6 months post-induction therapy) from Patient 2 had 
increase mtDNA copies/cell (104 copies/cell), which corre-
sponded to the MD/PRD-positive status of the same speci-
men (Fig. 1A). The Visit 3 follow-up CSF specimen from 
the same patient showed clearance of the MD/PRD status 
with matching decrease in mtDNA copies/cell (Fig. 1A), and 
the patient remained in clinical remission through the end of 
therapy.
     The CSF analyses from the next two patients showed 
parallel changes in MD/PRD status and mtDNA copy num-
bers/cell. Patients 3 and 4 both had clinical CNS disease at 
diagnoses; and both CSF specimens at diagnoses were MD/
Figure 1. Relationship of mtDNA copy numbers/cell and positive/negative-minimal disease/persistent or residual disease (MD/
PRD) Status. A) Cerebrospinal fluid (CSF) status of Patients 1 - 4 demonstrating relationship of MD/PRD-positive (black bar) and 
MD/PRD-negative (white bar) status with mtDNA copy number/cell (Y-axis). B) Peripheral blood mononuclear cells (PBMC) status 
of Patients 5 - 4 demonstrating relationship of MD/PRD-positive (black bar) and MD/PRD-negative (white bar) status with mtDNA 
copy number/cell (Y-axis). mtDNA copy numbers/cell for control or non-malignant cells range from 40 - 99 copies/cell [8].
Figure 2. Association of CSF mtDNA copy numbers/cell with 
positive/negative-minimal  disease/persistent  or  residual  dis-
ease (MD/PRD) status.
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PRD-positive. While the diagnostic CSF for Patient 3 had 
high mtDNA copies/cell at diagnosis (191 copies/cell), in 
contrast, the diagnostic CSF from Patient 4 was low (63 cop-
ies/cell); even though both children had clinical CNS disease 
initially. Both Patients 3 and 4 developed CNS relapse with-
in one year of diagnosis; and both patients had CSF speci-
mens during the first year that were MD/PRD-positive and 
had high mtDNA copies/cell, 173 copies/cell at Visit 2 and 
143 copies/cell at Visit 3, respectively.
    To assess the relationship of mtDNA copy numbers/cell in 
PBMC in children with ALL, Patients 5 and 6 were selected 
because both children developed relapse of their leukemia 
within one year of diagnoses. From both Patients 5 and 6, 
their PBMC specimens from Visits 2 were MD/PRD-posi-
tive and both had relatively high mtDNA copy numbers, 669 
and 478 copies/cell, respectively; compared to the Visit 1 
(one month post-induction therapy) PBMC specimens which 
were MD/PRD-negative and had mtDNA values of 127 and 
156 copies/cell, respectively. Of interest was the fact that 
both Visit 2 PBMC specimens for Patients 5 and 6 had high 
mtDNA copies/cell in the presence of MD/PRD-negative 
status in the same specimens; and these two children had 
bone marrow relapses within the first year of therapy (Table 
1). Both children underwent reinduction at the time of clini-
cal relapse and remained in remission at the end of therapy. 
Discussion
  
The overall objective of this study was to determine the abil-
ity and feasibility of measuring mitochondrial DNA (mtD-
NA) copies per cell in CSF cells from children diagnosed 
with ALL in the context of the presence or absence of MD/
PRD. The rationale for looking at CSF cells in childhood 
ALL cases in the context of mtDNA copy numbers for the 
current study focused on the fact that CSF lymphoblasts, 
when  present,  typically  make  up  a  higher  percentage  of 
cells in the CSF [14]. The design and methodology of the 
study did not sort CSF cells into subsets, i.e. lymphoblasts, 
therefore, the assumption was made that the mtDNA analy-
ses from the sample represented the median copy number/
cell. In this study, we report for the first time that MD/PRD-
positive CSF specimens from children with ALL had high 
mtDNA copy numbers/cell compared to MD/PRD-negative 
specimens; and the possibility that MD/PRD-positive CSF 
specimens with an increase in mtDNA are associated with 
risk for CNS relapse. The data in context with other studies 
of mtDNA and relapse might suggest that a compensatory 
increase in mtDNA copy number per cell could represent a 
survival phenotype that leads to relapse in patients [8].
In conclusion, this study was designed as a proof-of-
concept to test the feasibility of measuring mtDNA copy 
numbers from CSF specimens. Limitations of the study de-
sign center around the number of cases analyzed. Expanded 
studies are necessary to address the hypothesis that children 
with ALL who have MD/PRD-positive CSF specimens with 
high mtDNA copy numbers per cell may be at risk for CNS 
relapse. CNS relapse remains a major cause of morbidity in 
childhood ALL with treatment failure attributable to de novo 
or acquired resistance to a wide variety of cytotoxic drugs 
such as multi drug resistance [15, 16]. Additional factors as-
sociated with cell survival and phenotype leading to increase 
in mtDNA may also play a role in CNS relapse [8, 9]. In 
summary, this feasibility study warrants expanded analyses 
of additional children with ALL to determine the role that 
increased mtDNA copies in MD/PRD-positive cells in CSF 
and PBMC play in relapse disease.
 
Acknowledgments 
Supported  in  part  by  NIH  Grants  #CA121955, 
#P20RR011091;  and  the  Hawaii  Community  Foundation 
Grant  #20061478;  and  the  University  of  Hawaii  John A. 
Burns School of Medicine Department of Pediatrics. The 
views expressed in this manuscript are those of the authors 
and do not reflect the official policy or position of the De-
partment of the Army, Department of Defense, or the U.S. 
Government.
References
1.  Biondi A, Valsecchi MG, Seriu T, D’Aniello E, Willemse 
MJ, Fasching K, Pannunzio A, et al. Molecular detection 
of minimal residual disease is a strong predictive fac-
tor of relapse in childhood B-lineage acute lymphoblas-
tic leukemia with medium risk features. A case control 
study of the International BFM study group. Leukemia 
2000;14(11):1939-1943.
2.  Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald 
A.  Flow  cytometric  follow-up  of  minimal  residual 
disease in bone marrow gives prognostic information in 
children with acute lymphoblastic leukemia. Leukemia 
2003;17(1):138-148.
3.  Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, 
Behm FG, Raimondi SC, Sandlund JT, et al. Clinical im-
portance of minimal residual disease in childhood acute 
lymphoblastic leukemia. Blood 2000;96(8):2691-2696.
4.  de Haas V, Breunis WB, Verhagen OJ, van der Berg H, 
van der Schoot CE. Accurate quantification of minimal 
residual  disease  at  day  15,  by  real-time  quantitative 
polymerase chain reavtion identifies also patients with 
B-precursor acute lymphoblastic leukemia at high risk 
for relapse. Blood 2000;96(4):1619-1620.
5.  Dworzak MN, Froschl G, Printz D, Mann G, Potschger 
U, Muhlegger N, Fritsch G, et al. Prognostic significance 
and modalities of flow cytometric minimal residual dis-
   227                                   228J Clin Med Res  •  2010;2(5):225-229           Mitochondrial DNA in CNS ALL Relapse
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
ease detection in childhood acute lymphoblastic leuke-
mia. Blood 2002;99(6):1952-1958.
6.  Borowitz  MJ,  Devidas  M,  Hunger  SP,  Bowman WP, 
Carroll AJ, Carroll WL, Linda S, et al. Clinical signifi-
cance of minimal residual disease in childhood acute 
lymphoblastic  leukemia  and  its  relationship  to  other 
prognostic factors: a Children’s Oncology Group study. 
Blood 2008;111(12):5477-5485.
7.  Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devi-
das M, Borowitz MJ, Carroll AJ, et al. Risk- and re-
sponse-based  classification  of  childhood  B-precursor 
acute lymphoblastic leukemia: a combined analysis of 
prognostic markers from the Pediatric Oncology Group 
(POG)  and  Children’s  Cancer  Group  (CCG).  Blood 
2007;109(3):926-935.
8.  Kusao I, Agsalda M, Troelstrup D, Villanueva N, Shi-
ramizu B. Chemotoxicity recovery of mitochondria in 
non-Hodgkin lymphoma resulting in minimal residual 
disease. Pediatr Blood Cancer 2008;51(2):193-197.
9.  Kusao I, Troelstrup D, Shiramizu B. Possible Mitochon-
dria-Associated Enzymatic Role in Non-Hodgkin Lym-
phoma  Residual  Disease.  Cancer  Growth  Metastasis 
2008;1(3-8).
10.  Shiramizu B, C.L. Early detection of central nervous 
system relapse in childhood acute lymphoblastic leuke-
mia by polymerase chain reaction. International J Ped 
Hem/Onc, 1995;1:605-610.
11.  Shiramizu B., E.A., et. al. Monitoring of cerebral spinal 
fluid by polymerase chain reaction in children with acute 
lymphoblastic leukemia. International J Ped Hem/Onc, 
1998;5:475-483.
12.  Sabesan, V., M.S. Cairo, M.A. Lones, et al. Assessment 
of minimal residual disease in childhood non-hodgkin 
lymphoma by polymerase chain reaction using patient-
specific primers. J Pediatr Hematol Oncol, 2003;25(2): 
109-13.
13.  Shiramizu B, Shikuma KM, Kamemoto L, Gerschenson 
M, Erdem G, Pinti M, Cossarizza A, et al. Placenta and 
cord blood mitochondrial DNA toxicity in HIV-infected 
women  receiving  nucleoside  reverse  transcriptase 
inhibitors  during  pregnancy.  J Acquir  Immune  Defic 
Syndr 2003;32(4):370-374.
14.  Goldsby RE, Morgan JG, Egger MJ, Feusner J. Lym-
phoblast morphology in predicting leukemic meningeal 
relapse with low chamber count and lymphoblasts. Med 
Pediatr Oncol 1997;29(2):98-102.
15.  Kourti M, Vavatsi N, Gombakis N, Sidi V, Tzimagiorgis 
G, Papageorgiou T, Koliouskas D, et al. Expression of 
multidrug resistance 1 (MDR1), multidrug resistance-
related protein 1 (MRP1), lung resistance protein (LRP), 
and  breast  cancer  resistance  protein  (BCRP)  genes 
and clinical outcome in childhood acute lymphoblastic 
leukemia. Int J Hematol 2007;86(2):166-173.
16.  Kourti M, Vavatsi N, Gombakis N, Tzimagiorgis G, Sidi 
V, Koliouskas D, Athanassiadou F. Increased expression 
of multidrug resistance gene (MDR1) at relapse in a 
child with acute lymphoblastic leukemia. Pediatr Hema-
tol Oncol 2006;23(6):489-494.
   229                                   